Abstract:Nanobodies, also known as VHHs, originate from the serum of Camelidae. Nanobodies have considerable advantages over conventional antibodies, including smaller size, more modifiable, and deeper tissue penetration, making them promising tools for immunotherapy and antibody-drug development. A high-throughput nanobody screening platform is critical to the rapid development of nanobodies. To date, droplet-based microfluidic systems have exhibited improved performance compared to the traditional phage display technology in terms of time and throughput. In realistic situations, however, it is difficult to directly apply the technology to the screening of nanobodies. Requirements of plasma cell enrichment and high cell viability, as well as a lack of related commercial reagents, are leading causes for impeding the development of novel methods. We overcame these obstacles by constructing a eukaryotic display system that secretes nanobodies utilizing homologous recombination and eukaryotic transformation technologies, and the significant advantages are that it is independent of primary cell viability and it does not require plasma cell enrichment in advance. Next, a signal capture system of "SA-beads + Biotin-antigen + nanobody-6 × His + fluorescence-labeled anti-6 × His (secondary antibody)" was designed for precise localization of the eukaryotic-expressed nanobodies in a droplet. Based on this innovation, we screened 293T cells expressing anti-PD-L1 nanobodies with a high positive rate of targeted cells (up to 99.8%). Then, single-cell transcriptomic profiling uncovered the intercellular heterogeneity and BCR sequence of target cells at a single-cell level. The complete complementarity determining region (CDR3) structure was obtained, which was totally consistent with the BCR reference. This study expanded the linkage between microfluidic technology and nanobody applications and also showed potential to accelerate the rapid transformation of nanobodies in the large-scale market.

Cell-based Screening of Phage Antibody Library

Semi-Automated Cell Panning for Efficient Isolation of FGFR3-Targeting Antibody

Antibody Library Screening Using Yeast Biopanning and Fluorescence-Activated Cell Sorting

A Novel Strategy for Proteome-wide Ligand Screening Using Cross-linked Phage Matrices

Subtractive panning for the isolation of monoclonal PEPITEM peptide antibody by phage display

Discovery of antibodies targeting multipass transmembrane proteins using a suspension cell-based evolutionary approach

Recognition of cell surface proteins by high-density phage antibody chip

Magnetic Nanoparticle-Based Semi-Automated Panning for High-Throughput Antibody Selection

Selection of Antigen Binders from a Chicken Single-Chain Variable Fragment Library

Isolation of Antibody Binders to MISIIR from a Phage Display Library by Sorting

Screening Tumor-Targeting Bacteriophage Particles by Pre-Clearing Phage Display

A biosensor-based phage display selection method for automated, high-throughput Nanobody discovery

Development of a Phage Display Panning Strategy Utilizing Crude Antigens: Isolation of MERS-CoV Nucleoprotein human antibodies

[Phage antibody library technology in tumor therapy: a review].

Function-based High-Throughput Screening for Antibody Antagonists and Agonists Against G Protein-Coupled Receptors

The role of phage display in therapeutic antibody discovery

Modification of phage display technique for improved screening of high-affinity binding peptides

Application of Microfluidic Technology in Antibody Screening

Generation and Screening of Antigen-Specific Nanobodies from Mammalian Cells Expressing the BCR Repertoire Library Using Droplet-Based Microfluidics

A compact phage display human scFv library for selection of antibodies to a wide variety of antigens

The Improvement in Screening for Vascular Endothe Lial Growth Factor Receptor Flt-1 Antagonists in a Phage Display Library